Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma

被引:405
作者
Yu, JS
Liu, GT
Ying, H
Yong, WH
Black, KL
Wheeler, CJ
机构
[1] Cedars Sinai Med Ctr, Maxine Dunitz Neurosurg Inst, Los Angeles, CA 90048 USA
[2] Cedars Sinai Med Ctr, Dept Pathol, Los Angeles, CA 90048 USA
关键词
D O I
10.1158/0008-5472.CAN-03-3505
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The primary goal of this Phase I study was to assess the safety and bioactivity of tumor lysate-pulsed dendritic cell (DC) vaccination to treat patients with glioblastoma multiforme and anaplastic astrocytoma. Adverse events, survival, and cytotoxicity against autologous tumor and tumor-associated antigens were measured. Fourteen patients were thrice vaccinated 2 weeks apart with autologous DCs pulsed with tumor lysate. Peripheral blood mononuclear cells were differentiated into phenotypically and functionally confirmed Ms. Vaccination with tumor lysatepulsed DCs was safe, and no evidence of autoimmune disease was noted. Ten patients were tested for the development of cytotoxicity through a quantitative PCR-based assay. Six of 10 patients demonstrated robust systemic cytotoxicity as demonstrated by IFN-gamma expression by peripheral blood mononuclear cells in response to tumor lysate after vaccination. Using HLA-restricted tetramer staining, we identified a significant expansion in CD8+ antigen-specific T-cell clones against one or more of tumor-associated antigens MAGE-1, gp100, and HER-2 after DC vaccination in four of nine patients. A significant CD8+ T-cell infiltrate was noted intratumorally in three of six patients who underwent reoperation. The median survival for patients with recurrent glioblastoma multiforme in this study (n = 8) was 133 weeks. This Phase I study demonstrated the feasibility, safety, and bioactivity of an autologous tumor lysate-pulsed DC vaccine for patients with malignant glioma. We demonstrate for the first time the ability of an active immunotherapy strategy to generate antigen-specific cytotoxicity in brain tumor patients.
引用
收藏
页码:4973 / 4979
页数:7
相关论文
共 24 条
[1]   INTRATUMORAL LAK CELL AND INTERLEUKIN-2 THERAPY OF HUMAN GLIOMAS [J].
BARBA, D ;
SARIS, SC ;
HOLDER, C ;
ROSENBERG, SA ;
OLDFIELD, EH .
JOURNAL OF NEUROSURGERY, 1989, 70 (02) :175-182
[2]  
Black K L, 1999, Clin Neurosurg, V45, P160
[3]  
Davis FG, 2001, NEURO-ONCOLOGY, V3, P152, DOI 10.1093/neuonc/3.3.152
[4]   Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells [J].
Hsu, FJ ;
Benike, C ;
Fagnoni, F ;
Liles, TM ;
Czerwinski, D ;
Taidi, B ;
Engleman, EG ;
Levy, R .
NATURE MEDICINE, 1996, 2 (01) :52-58
[5]   Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination [J].
Kammula, US ;
Marincola, FM ;
Rosenberg, SA .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (16) :1336-1344
[6]  
Kammula US, 1999, J IMMUNOL, V163, P6867
[7]   RETRACTED: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids (Retracted article. See vol. 9, p. 1221, 2003) [J].
Kugler, A ;
Stuhler, G ;
Walden, P ;
Zöller, G ;
Zobywalski, A ;
Brossart, P ;
Trefzer, U ;
Ullrich, S ;
Müller, CA ;
Becker, V ;
Gross, AJ ;
Hemmerlein, B ;
Kanz, L ;
Müller, GA ;
Ringert, RH .
NATURE MEDICINE, 2000, 6 (03) :332-336
[8]   HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells [J].
Liu, G ;
Ying, H ;
Zeng, G ;
Wheeler, CJ ;
Black, KL ;
Yu, JS .
CANCER RESEARCH, 2004, 64 (14) :4980-4986
[9]   Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma [J].
Liu, GT ;
Khong, TT ;
Wheeler, CJ ;
Yu, JS ;
Black, KL ;
Ying, H .
JOURNAL OF IMMUNOTHERAPY, 2003, 26 (04) :301-312
[10]   THE JAM TEST - A SIMPLE ASSAY FOR DNA FRAGMENTATION AND CELL-DEATH [J].
MATZINGER, P .
JOURNAL OF IMMUNOLOGICAL METHODS, 1991, 145 (1-2) :185-192